Avextra – die Essenz zeitgemäßer Cannabis-Medizin. Evidenzbasiert. Das Handelsblatt hat das hessische Cannabis-Biotech-Unternehmen Avextra porträtiert und gibt Einblicke in die Arzneimittelentwicklung Made in Germany. Aktueller Medienbericht Weiterlesen Avextra arbeitet mit Forscher:innen und medizinischen Fachkräften zusammen, um Real-World Patientendaten und RCTs zu erheben und auszuwerten, die zur Zulassung evidenzbasierter Cannabisarzneimittel herangezogen werden können. Extra Evidenz: weitere Informationen Lernen Sie im Video mit unserem CMO David Reckeweg-Lecompte mehr über die Kultivierung von medizinischem Cannabis und die hochmoderne GMP-Herstellung bei Avextra in Deutschland. Avextra:
Qualität Charge für Charge
zur Video-Übersicht
Den Einsatz von cannabisbasierten Arzneimitteln ausweiten durch innovative, rigoros getestete und behördlich zugelassene Produkte. Unsere Mission: mehr Infos Das therapeutische Potenzial der Cannabispflanze verstehen und nutzen, für eine Verbesserung der Lebensqualität von Patient:innen. Unsere Vision: mehr Infos

Avextra – the essence
of cannabis-based medicine is evidence.
The Leading German Business Publication Handelsblatt did a profile on the German cannabis biotech company Avextra providing insights into botanical drug development Made in Germany. News More Information Avextra collaborates with researchers and healthcare professionals to collect and aggregate real world patient data and RCTs to inform and support regulatory filings. Extra Evidenz: Read more Watch this video with our CMO David Reckeweg-Lecompte to learn more about cultivating medicinal cannabis and Avextra’s state-of-the-art GMP manufacturing facility in Germany. Avextra: quality batch by batch Go to our media section To expand the use of cannabis-based medicines through innovative, rigorously tested, and regulatory-approved products. Our mission: Read more To understand and use the therapeutic potential of the cannabis plant to improve the quality of life of patients. Our vision: Read more

L’essenza della medicina a base di cannabis The Leading German Business Publication Handelsblatt did a profile on the German cannabis biotech company Avextra providing insights into botanical drug development Made in Germany.

News Ulteriori informazioni
Guardate questo video con il nostro CMO David Reckeweg-Lecompte per saperne di più sulla coltivazione della cannabis terapeutica e sullo stabilimento di produzione GMP all’avanguardia di Avextra in Germania. Avextra: qualità lotto per lotto Vai alla sezione media Rendere i farmaci a base di cannabis disponibili per un’ampia popolazione di pazienti attraverso lo sviluppo di prodotti innovativi, rigorosamente testati e approvati dalle autorità regolatorie. La nostra mission: Per saperne di più Comprendere e utilizzare il potenziale terapeutico della pianta di cannabis per migliorare la qualità della vita dei pazienti. La nostra vision: Per saperne di più

Cannabisbasierte Arzneimittel von Avextra

Avextra is extra

Because we take quality seriously, we control the full value chain of our products from growing to manufacturing and distribution

We have over 75 years of experience in botanical extraction and in manufacturing plant-based medicines.

We are fully committed to gathering and documenting evidence to support the therapeutic potential of cannabis-based medicines

Avextra collaborates with researchers and healthcare professionals to collect and aggregate real world patient data and RCTs to inform and support regulatory filings.

RESEaRCH & DEVELOPMENT

What differentiates Avextra from the rest?

  • We invest one-third of our total budget in research and development
  • We are focused on expanding the evidence base for therapy with cannabis-based medicines
  • Ensure the efficacy and quality of our products
  • Innovation is part of our DNA

Avextra‘s clinical trials and observational studies

Here you can find out more about Avextra's clinical program and the ongoing studies.

The Avextra Alliance for evidence-based Cannabis-Medicine

  • Focused on collaborating with researchers, doctors and scientific associations
  • To generate real world patient data in medical cannabis access programs
  • With the aim of designing robust clinical trials for proprietary Cannabis-based medicines that can achieve regulatory approval

We are Specialists for Plant-Based Medicines

Patients in focus: Patients do not suffer from their illnesses alone but also from the symptoms and burdens of coping with serious illness. The goal of our research is to develop cannabis-based products that have proven effective in relieving symptoms.

Avextra's Cultivation in Portugal

Check out our state-of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes tour!


VaLUE CHaIN

Complete control over the full value chain

Because cannabis has historically not been cultivated at scale for pharmaceutical production, developing cannabis-based medicines that comply fully with EU quality standards, requires an investment in the full production value chain

Our best guarantee for reliable and secure supply for our pharmaceutical production

EXPERT aREA

Service, Information and Documentation for Healthcare Professionals

Expert Area for Physicians

  • Applications and Forms
  • scientific publications

Expert Area for Pharmacists

  • Availability of Products
  • Identity Verification
  • Application for prescription

Memberships

VCA - ASSOCIATION OF CANNABIS SUPPLYING PHARMACIES E.V.

The VCA is the professional association for pharmacies supplying cannabis in Germany. It is focused on developing competence, offers further education and promotes the exchange of content between pharmacists, industry, science and politics. The declared goal of the VCA is to ensure an efficient and affordable supply of medical cannabis to patients in Germany.

Cooperation Partners

EN